Cardio Diagnostics Holdings, Inc. (CDIO): EBITDA
-$6.42M
Year ended 2025-12-31
-$6.44M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$6.42M | n/m | 2026-03-13, From 2025-01-01 |
| 2024-12-31 | -$8.35M | n/m | 2026-03-13, From 2024-01-01 |
| 2023-12-31 | -$7.22M | n/m | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | -$4.53M | n/m | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | -$604.4K | n/a | 2023-03-31, From 2021-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | 2025-12-31 | -$6.42M | n/m |
| Celldex Therapeutics, Inc. (CLDX) | 2025-12-31 | -$283.99M | n/m |
| Volitionrx Ltd (VNRX) | 2025-12-31 | -$20.75M | n/m |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | -$48.93M | n/m |
| Biomerica Inc (BMRA) | 2026-05-31 | -$5.24M | n/m |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | -$7.80M | n/m |
| Immucell Corp (ICCC) | 2025-12-31 | $4.43M | +306.8% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | -$10.63M | n/m |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | -$431.22M | n/m |
Compare CDIO, CLDX, VNRX, IMDX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗